KROST
MARCH 2, 2021
This is one of the article in the KROST Quarterly Manufacturing Issue , titled “Relief Comes in the Form of R&D Tax Credits for Manufacturing Companies” by Guest Contributor, Michael Maroney. These companies include pharmaceutical, clothing, technology, cosmetics, textile, and others. Read the full Manufacturing Issue ».
Going Concern
MAY 23, 2024
His diverse industry experience includes pharmaceutical, biotech, manufacturing, chemicals, semiconductors, retail, and finance. Based in Massachusetts, Rinke has more than two decades of international tax experience, notably involving cross-border transactional and operational planning for multinational corporations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CPA Practice
JANUARY 2, 2024
He has extensive experience managing Public Company Accounting Oversight Board (PCAOB) audits in the United States, many of which he led through the Initial Public Offering (IPO) process.
PYMNTS
JANUARY 23, 2019
If one wants to understand the complexities of the pharmaceutical supply chain, just follow the money. Contract negotiations between drug manufacturers, wholesalers, hospitals, pharmacies and their group purchasing organizations (GPOs) are ever-changing, meaning B2B payments are often incorrect, and chargebacks and disputes are common.
PYMNTS
SEPTEMBER 2, 2020
And it is upending healthcare too, perhaps most visibly in pharmaceuticals, where we can get our meds mailed, on autopilot. The direct to consumer ( DTC) model is changing the way we get our goods and services across everything from makeup to meal kits.
PYMNTS
JUNE 2, 2020
Healthcare providers, insurance companies and pharmaceutical manufacturers across the U.S. Funding Pharmaceuticals Fast. Some patients require daily or weekly medical treatments, meaning they must be equipped to handle years of pharmaceutical costs. Slow, paper-based payments do more than cause speedbumps in operations.
Withum
DECEMBER 7, 2023
Covered entities have had to navigate temporary COVID-19 regulations, manufacturer restrictions, and, now, prospective changes to their patient definition. The result of the court ruling opens providers to broader access to 340B discounts, which would likely increase cost savings on pharmaceuticals.
Expert insights. Personalized for you.
78 
Let's personalize your content